OKYO Pharma Ltd (NASDAQ:OKYO) said its executive chairman, Gabriele Cerrone, has lifted his stake after Panetta Partners, an entity he benefits from, bought 82,018 shares on Nasdaq. Cerrone now holds 10,464,695 shares.
The company is developing urcosimod, a late-stage candidate for neuropathic corneal pain and dry eye disease.